Table 2.
Outcome of younger (<60 years) AML patients
| 2000–2004 | 2005–2009 | 2010–2014 | P | |
|---|---|---|---|---|
| N = 173 | N = 181 | N = 159 | ||
| Day-60 death, n (%) | 16 (9.2) | 15 (8.3) | 7 (4.4) | 0.207 |
| CR1, n (%) | 141 (81.5) | 148 (81.8) | 137 (86.2) | 0.449 |
| Induction failure, n (%) | 18 (10.4) | 22 (12.2) | 14 (8.8) | 0.603 |
| Allo-SCT in CR1, n (%) | 43 (30.5) | 57 (38.5) | 71 (51.8) | 0.001 |
| Auto-SCT in CR1, n (%) | 41 (29.1) | 20 (13.5) | 3 (2.2) | <0.001 |
| CR2, n (%) | 20/68a (29.4) | 30/60a (50.0) | 22/47a (46.8) | 0.040 |
| Allo-SCT in CR2, n (%) | 0(0) | 1 (3.3) | 9 (40.9) | <0.001 |
| Clinical trial, n (%) | 98 (56.6) | 46 (25.4) | 49 (30.8) | <0.001 |
| Median DFS, months (IQR) | 25.1 (8.3-NR) | 23.5 (7.5-NR) | 43.4 (11.9-NR) | 0.381 |
| Median OS, months (IQR) | 24.4 (8.7-NR) | 26.6 (9.1-NR) | NR (13.4-NR) | 0.035 |
CR1 first complete response, CR2 second complete response, DFS disease-free survival, IQR interquartile range, OS overall survival, SCT stem cell transplantation
aRelapses after CR1